Parkinson’s disease is a movement disorder of the nervous system that affects millions worldwide, and as researchers continue to unravel its intricacies, the future looks …
Our Perspectives, Ideas & Research on Drug Discovery | Gain Therapeutics
How are human clinical trials conducted? Before human trials even begin, animal trials are conducted first to evaluate safety. Once human trials begin, they move …
This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment …
24 Sep: Ryan Reynolds Shares His Father’s Early Parkinson’s Symptoms: Subtle Signs His Family Missed
Ryan Reynolds, the charismatic star of “Deadpool & Wolverine,” recently opened up about his father’s battle with Parkinson’s disease, shedding light on the early symptoms …
Biomarkers and their use in therapeutic development Biomarkers are specific characteristics that can be used to predict the risk of disease, identify the presence of …
Summary: At the Annual Neuro Perspectives Virtual Conference hosted June 27th, H.C. Wainwright hosted a Fireside Chat with Ram Selvaraju, a Senior Healthcare Equity Research …
Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is …
Neurodegenerative diseases and the immune system Neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, Huntington’s, and Motor Neuron diseases, are generally thought of in their capacity as …
Read the research article in full. Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease (LSD) that arises from mutations in the gene …
The new CFO fills in the missing link When you think of a Chief Financial Officer, the first thing that comes to mind is not …
The links between Alzheimer’s, Parkinson’s, and Prion diseases At first glance, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and prion disease share many generalized features. While …
Part 3 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 3 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
Part 2 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 2 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
What this means for the future of Parkinson’s disease On May 23, 2024, Congress officially passed the National Plan to End Parkinson’s Act (H.R.2365/S.1064). The …
Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.
Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.
Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.
Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.
What Makes a Truly Valuable AI Drug Discovery Platform? The value in AI drug discovery platforms lies in their ability to target known, yet previously …
Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors …
Watch the video from 50 sec onwards to learn hear about Gain Therapeutics Gain Therapeutics was mentioned on Fox Business News as a company to …
Beatriz Calvo-Flores Guzman, presented at the 20th Annual WORLDSymposium discussing preclinical data demonstrating that our clinical-stage GCase regulator provided neuroprotection & restored motor function in …
This webinar, hosted by Force Family Office, features Gain Therapeutics, a biotech company developing treatments for Parkinson’s disease and other neurodegenerative diseases. The speakers are …
Gain Therapeutics will be attending JP Morgan HealthCare Conference Jan 8th to 11th, 2024 in San Francisco. Representing will be: CEO Matthias Alder CFO Evan …
“The published data propose that strategies to alleviate dysfunction such as targeting GCase could be a new therapeutic opportunity for neurodegenerative diseases and lysosomal storage …
Gain’s Clinical Candidate GT-02287 Earlier this month, Gain Therapeutics announced the dosing of the first two subjects in a Phase 1 clinical trial of GT-02287, …
In an engaging interview, journalist Jane King from LilaMax Media discusses cutting-edge allosteric therapies with Gain Therapeutics’ CEO, Matthias Alder, and their potential in …